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Abstract
Leukotrienes play a central pathophysiological role in both paediatric and adult asthma.
However, 35% to 78% of asthmatics do not respond to leukotriene inhibitors. In this study
we tested the role of the LTA4H regulatory variant rs2660845 and age of asthma onset in
response to montelukast in ethnically diverse populations. We identified and genotyped
3,594 asthma patients treated with montelukast (2,514 late-onset and 1,080 early-onset)
from seven cohorts (UKBiobank, GoSHARE, BREATHE, Tayside RCT, PAGES, GALA II
and SAGE). Individuals under montelukast treatment experiencing at least one exacerba-
tion in a 12-month period were compared against individuals with no exacerbation, using
logistic regression for each cohort and meta-analysis. While no significant association was
found with European late-onset subjects, a meta-analysis of 523 early-onset individuals
from European ancestry demonstrated the odds of experiencing asthma exacerbations by
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carriers of at least one G allele, despite montelukast treatment, were increased (odds-
ratio = 2.92, 95%confidence interval (CI): 1.04–8.18, I2 = 62%, p = 0.0412) compared to
those in the AA group. When meta-analysing with other ethnic groups, no significant
increased risk of asthma exacerbations was found (OR = 1.60, 95% CI: 0.61–4.19, I2 =
85%, p = 0.342). Our study demonstrates that genetic variation in LTA4H, together with tim-
ing of asthma onset, may contribute to variability in montelukast response. European indi-
viduals with early-onset (�18y) carrying at least one copy of rs2660845 have increased odd
of exacerbation under montelukast treatment, presumably due to the up-regulation of
LTA4H activity. These findings support a precision medicine approach for the treatment of
asthma with montelukast.
Introduction
Asthma is a common chronic inflammation of the airways manifesting as shortness of breath,
wheeze and chest tightness that can lead to death, especially in older adults. With around 339
million affected people worldwide [1] and an increase in incidence over recent decades,
asthma is still under-diagnosed and under treated. The wide variation observed within
asthma-related traits, including age of onset, respiratory symptoms, risk factors, frequency of
exacerbations, lung function, comorbidities, and underlying inflammatory patterns, provide
difficulty for diagnosis and are believed to contribute to heterogeneous treatment response.
Although asthma is recognised as a heterogenous disease, conventional stratification of rel-
evant asthma subgroups is mainly limited to Th2-high (eosinophilic) or Th2-low (non-eosino-
philic) according to the level of type 2 helper T cell (Th2) cytokine mediated eosinophilic
airway inflammation. Other current biomarkers of airway inflammation, such as immuno-
globulin E (IgE), or fraction of exhaled nitric oxide (FeNO), are also used clinically to target
treatment and predict future risk [2]. In the recent years, new clinical biomarkers of asthma
phenotype such as disease severity, exacerbation triggers and comorbidities have been widely
used, with the age of onset of asthma and genetic risk factors recently emerging [3–7]. Early-
onset asthma is typically Th2-high atopic or allergic and responsive to steroids. Late-onset
asthma is more diverse than early-onset asthma and presents with both Th2-high and Th2-low
types with the latter being associated to non-atopy or lifestyle (smoking, obesity) and being
characterised by a non-response to steroid therapy [8]. Although asthma shares common
genetics with allergic diseases [9], none all individuals with allergic asthma respond to steroids
[10]. This add to the emerging evidence of asthma genetic heterogeneity defining different
underlying biological mechanisms, which should help predict the patients’ likely responses to
treatment [11].
Leukotriene modifiers are pharmacological therapies for the treatment of asthma and aller-
gic rhinitis. As established through numerous clinical trials, drugs such as montelukast have
been shown to be effective in improving lung function, asthma control and quality of life, by
reducing airway hyperresponsiveness and eosinophilia [12]. Recent guidelines for the manage-
ment of asthma in children and adults from the National Institute for Health and Clinical
Excellence (NICE), highlighted leukotriene receptor antagonists (LTRA) as a key part of
asthma management and recommended their use as the first line add-on therapy for persistent
asthmatic patients who still show symptoms despite low dose of inhaled corticosteroids (ICS)
[13]. However, a range of 35 to 78 percent of the patients treated with leukotriene inhibitors
such as montelukast were found unresponsive across several independent studies [10, 14–17].
PLOS ONE LTA4H role in montelukast response
PLOS ONE | https://doi.org/10.1371/journal.pone.0257396 September 22, 2021 2 / 17
Vijverberg at s.j.vijverberg@amc.nl (http://pica-
consortium.org). The SHARE Bioresources
(GoSHARE) is accessible with an approved
application to studies@registerforshare.org.
Similarly, the UK Biobank requires study-specific
approvals (application form in the UK Biobank
online Access Management System (AMS) https://
www.ukbiobank.ac.uk), and the individual level
data cannot be publicly shared.
Funding: The UKBB was accessed through AZ’s
MTA (application number 26041). BREATHE was
funded by Scottish Enterprise Tayside, the
Gannochy trust, the Perth and Kinross City Council
and Brighton and Sussex Medical School. Tayside
RCT is supported by Merck, Sharpe & Dohme,
United Kingdom. PAGES was funded by the Chief
Scientist Officer for Scotland. The SHARE
Bioresource (GoSHARE) and SHARE have ongoing
funding from NHS Research Scotland and
established by funding from The Wellcome Trust
Biomedical Resource [Grant No. 099177/Z/12/Z].
The GoDARTS study was funded by The Wellcome
Trust (Award 072960 and 084726) and the UK
Medical Research Council (Award G0601261).
Genotyping of PAGES was funded by grant AC15/
00015 by Instituto de Salud Carlos III (ISCIII)
through Strategic Action for Health Research (AES)
and European Community (EC) within the Active
and Assisted Living (AAL) Programmed
framework, and by the SysPharmPedia grant. The
SysPharmPediA consortium is supported by
ZonMW [project number: 9003035001], the
Ministry of Education, Science and Sport of the
Republic of Slovenia [contract number C330-16-
500106], the German Ministry of Education and
Research (BMBF) [project number FKZ 031L0088],
Instituto de Salud Carlos III (ISCIII) through
Strategic Action for Health Research (AES) and
European Community (EC) within the Active and
Assisted Living (AAL) Programme framework
[award numbers AC15/00015 and AC15/00058]
under the frame of the ERACoSysMed JTC-1 Call.
Genotyping service was carried out at CEGEN-
PRB3-ISCIII; supported by grant PT17/0019, of the
PE I+D+i 2013-2016, funded by ISCIII and
European Regional Development Fund (ERDF).
GALA II and SAGE were supported by the NHLBI of
the United States National Institutes of Health (NIH)
through grants R01HL117004 and X01HL134589.
Additional study enrolment was supported by the
Sandler Family Foundation, the American Asthma
Foundation, the Amos Medical Faculty
Development Program from the Robert Wood
Johnson Foundation, the Harry Wm. and Diana V.
Hind Distinguished Professorship in
Pharmaceutical Sciences II, and the National
Institute of Environmental Health Sciences (NIEHS)
Asthma is a very heterogenous disease resulting from a complex interplay between genetic sus-
ceptibility and environment. Despite the ongoing efforts there are many patients with poorly
controlled asthma and with treatment based on symptomatology rather than underlying dis-
ease pathobiology. A precision medicine approach, based on genetic profiles, biomarkers mea-
sures and clinical assessments, is vital to target treatments to the patient population most likely
to benefit. Pharmacogenetic studies are therefore essential to the understanding of the genetic
interplay in drug response and identification of individuals best targeted treatments.
Pharmacogenetic studies have investigated candidate genes in the leukotriene pathway,
showing that interpatient variability might be influenced by genetic variation. Variants in
ALOX5, LTA4H, LTC4S, ABCC1, CYSLTR2, and SLCO2B1 genes may contribute to the het-
erogeneity of response to leukotriene modifiers, including montelukast [14, 18–20]. To date,
only the effect of a small number of genetic variants has been validated in independent studies
[10, 21]. We focused our analysis on a particular variant in the regulatory region of the leuko-
triene-A4 hydrolase (EC3.3.2.6) gene (LTA4H), the single nucleotide polymorphism (SNP)
rs2660845. This variant has been shown to influence montelukast response through the pre-
vention of exacerbations in a cohort of young adults with asthma from the United States [14]
as well as improvement of pulmonary parameters such as peak expiratory flow (PEF) and
forced expiratory volume in one second (FEV1) in a Japanese cohort [16]. However, the sam-
ple size of those studies was small, and the association observed between the rs2660845 SNP
and responsiveness to montelukast has not been validated.
In this study, we utilised a very large dataset, consisting of previously described, ethnically
diverse case-control studies (GALA II and SAGE), asthma cohorts (BREATHE and PAGES), a
randomised clinical trial (RCT) (Tayside RCT) and two large real-life cohorts (the UKBiobank
and GoSHARE), to explore the association of rs2660845 with lack of montelukast treatment
response. We also wished to determine if age of asthma onset status further refined this puta-
tive pharmacogenomic association to provide the beginnings of a precision medicine strategy
for the treatment of asthma with montelukast.
Methods
Study design
Asthmatic patients treated with montelukast for at least 6 months were included in this study.
We defined early-onset as individuals�18 years old at asthma diagnosis and late-onset for
individuals over 18 years old at asthma diagnosis.
Early-onset were recruited from five cross-sectional studies (PAGES, BREATHE, Tayside
RCT, GALA II and SAGE) as well as from one longitudinal study (GoSHARE, the Genetics of
Scottish Health Registry [22]). BREATHE, Tayside RCT and PAGES’ patients were recruited
from primary and secondary care in Scotland. BREATHE and Tayside RCT details of enrol-
ment have been presented in detail previously [23, 24]. PAGES, the Pediatric Asthma Gene
Environment Study, was an exploratory study of the genetic variation and exposure in asth-
matic Scottish children from various ethnicities [25]. The Genes-environments and Admixture
in Hispanics/Latinos (GALA II) study and the Study of African-Americans, Asthma, Genes,
and Environments (SAGE) recruited children from community- and clinic-based centers,
with GALA II focused on Hispanics/Latinos and SAGE focused on African Americans [26].
BREATHE, PAGES, GALA II and SAGE studies were all part of the Pharmacogenetics in
Childhood Asthma (PiCA) consortium [27]. For all studies from the PiCA consortium and
Tayside RCT, asthmatic individuals under montelukast treatment were selected by a physician
and information such as age, sex, BMI and OCS use, hospitalization and exacerbation were
available from a questionnaire filled at patient enrolment. In GoSHARE, asthma patients were
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selected from a dataset containing complete electronic medical records (EMR), prescription
information, hospital, and emergency room records (International Classification of Diseases
10th revision [ICD-10] codes J45) from Tayside, Scotland (S2 Table).
Late-onset individuals were recruited from the UKBiobank [28] and GoSHARE. In the
UKBiobank, selected asthma patients were British white individuals from self-reported ques-
tionnaires and hospital records (ICD10: J45) released in October 2019 by querying an AstraZe-
neca in-house protected UKBiobank database server. Other information on UKBiobank
individuals such as age of onset of asthma and sex were extracted from self-reported question-
naires whereas montelukast usage was extracted from the recent release of drug prescriptions
(October 2019). https://www.sciencedirect.com/science/article/pii/S2213260019300554-bib9
The studies included in this article comply with the Declaration of Helsinki, and locally
appointed ethics committee have approved respective research protocols and consent proce-
dures. Study participants for GoSHARE provided written informed consent to their data as
well as spare blood, left after routine venepuncture, to be held in NHS databases and used for
suitable research projects. For the UKBiobank, written consent form was filled by participants
on their enrolment in the different selected centre and witnessed and signed by an NHS staff
member. Written informed consent was obtained from the participants and/or parent/guard-
ian as relevant for PAGES, BREATHE, Tayside RCT, SAGE and GALAII studies. All data were
fully anonymized before granted access. PAGES was approved by the Cornwall and Plymouth
Research Ethics Committee (Plymouth, United Kingdom). GoSHARE, BREATHE and Tay-
side RCT were approved by the Tayside Committee on Medical Research Ethics (Dundee,
United Kingdom). The UKBiobank was approved by the National Research Ethics Committee.
The Human Research Protection Program Institutional Review Board of the University of Cal-
ifornia, San Francisco (San Francisco, United States) approved GALA II and SAGE (ethics
approval numbers: 217802 and 210362, respectively).
Asthma treatment was categorized following British Thoracic Society/Scottish Intercolle-
giate Guideline Network (BTS/SIGN) guidelines [29]. Only individuals on montelukast ther-
apy were selected for further analysis (S2 Table). Both late-onset and early-onset patients were
selected from the GoSHARE study. As age of asthma onset was not reported in the EMR for
GoSHARE, we use age at first salbutamol, age at first Inhaled corticosteroid and age at first
montelukast prescription, all three over 18 years old to characterize the late-onset group
GoSHARE(a) and all three under 18 years old to characterize the early-onset group GoSHARE
(b).
DNA collection, extraction and analysis
For BREATHE and Tayside RCT, saliva was collected in commercially available kits (Oragene,
DNA Genotech Ontario, Canada). DNA was prepared using the Qiagen DNeasy 96 kit (Qia-
gen, Manchester, UK) and genotypes were determined in the University of Dundee laboratory
using TaqMan™ based allelic discrimination arrays on an ABI 7700 sequence detection system
(ThermoFisher, Waltham, USA). For GoSHARE (a and b) respectively, DNA was extracted
from blood samples taken at recruitment or from a prescribed blood test and genotyped using
the Infinium Global Screening Array v2 (Illumina, San Diego, USA). Under the UKBiobank
project, all recruited individuals were genotyped using a purpose-designed genotypic array:
the UKBiobank Axiom Array. As part of the PiCA consortium, PAGES DNA was selected and
genotyped in the Spanish National Genotyping Center (CEGEN-PRB3-ISCIII), using the
Axiom Precision Medicine Research Array (PMRA) (Affymetrix, Thermo Fisher Scientific
Inc, Waltham, MA). GALA II and SAGE were genotyped using the Axiom LAT1 array (World
Array 4, Affymetrix, Santa Clara, CA, United States), as described elsewhere [30]. Studies with
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genome-wide genotyping data were subjected to standard quality control procedures, ensuring
that SNP genotyping call rate was above 95% and the absence of deviations from Hardy-Wein-
berg equilibrium (p>10–6) within control subjects. Samples with discrepancy between genetic
sex and reported sex and with family relatedness were removed from the analyses.
Binary risk of having an asthma exacerbation
The association between the variant of interest and the risk of having an asthma exacerbation
was tested. A binary variable related to the absence or presence of at least one exacerbation
event in a time frame of 6 to 12 months (0 = no exacerbation, 1 = at least one exacerbation
event) was used (Fig 1). Asthma exacerbations were defined based on the American Thoracic
Society (ATS)/European Respiratory Society (ERS) guidelines as episodes of worsening of
asthma symptoms which require a short course (3–5 days) of oral systemic corticosteroids
(OCS) use, hospitalizations or emergency department (ED) visits [31]. The definition was then
adapted to each study design and information available. Cross sectional studies collected data
on asthma treatment either from pharmacy records, parent/patient-reported medication use,
or completed study questionnaires, 6 months for BREATHE, Tayside RCT and PAGES or 12
months before enrolment for GALAII and SAGE. For PAGES, BREATHE and Tayside RCT,
the definition of exacerbation was at least one of the following in the previous six months of
recruitment: hospital admission, short course of oral corticosteroids (OCS) or absence from
school, all due to asthma symptoms and verified by a general practitioner or a nurse. For
GALA II and SAGE, asthma exacerbations were defined by the presence of at least one of the
following events in the 12 months preceding the study inclusion as available: need to seek
emergency asthma care, hospitalization, or the administration of OCS due to asthma symp-
toms. Response designed on prescription-based information in GoSHARE and UKBiobank
was gathered in a time frame of 12 months after date of first montelukast prescription. For the
UKBiobank and GoSHARE (a and b), the definition of exacerbation was at least one of the fol-
lowing within 12 months after first montelukast prescription date: hospital admission for
asthma symptoms (ICD10: J45), emergency room visit (ER) for asthma symptoms (ICD10:
J45), and two or more prescriptions of OCS. Non responders or cases, under montelukast
treatment, have at least one course of oral corticosteroids (OCS), hospitalisation, emergency
room visit and/or school absence within 6 months (T = time) before date of enrolment for
BREATHE, PAGES and Tayside RCT. For GALA II and SAGE, non-responders or cases have
at least one course of OCS, hospitalisation and/or emergency room visit within 12 months
before date of enrolment. For UKB and GoSHARE, non-responders or cases have at least 2
course of OCS, one hospitalisation and/or one emergency room visit within 12 months after
date of first montelukast prescription.
Fig 1. Graph of the binary risk of experiencing an exacerbation definition.
https://doi.org/10.1371/journal.pone.0257396.g001
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To verify the effect of rs2660845 on montelukast response and not just on exacerbation, we
tested the association between rs2660845 and exacerbation in non-montelukast users. In late-
onset, as we have longitudinal data for GoSHARE(a) cohort, individuals previously selected as
being under montelukast treatment where used. The binary effect of experiencing an exacerba-
tion was defined 12 months before start of therapy. In early-onset asthma, genetic data from
non-montelukast users were only available from PAGES, BREATHE GALA and SAGE
cohorts. Individuals were selected as not being under montelukast treatment at enrolment.
The binary risk of having an asthma exacerbation was defined as described before for PAGES,
BREATHE and GoSHARE. An asthma exacerbation was defined described before as well for
PAGES and BREATHE. For GoSHARE (a) and asthma exacerbation was described as at least
one of the following within 12 months before first montelukast prescription date: hospital
admission, emergency room visit, course of OCS and discontinuation of the drug. Study
details are presented in S3 Table.
Statistical analysis
Statistical analysis of PAGES, BREATHE, Tayside RCT, the UKBiobank and GoSHARE (a and
b) data were performed in SAS 9.3 (SAS Institute, Cary, NC, USA [32]) and PLINK 1.9 [33]
for GALA II and SAGE. Binary logistic regression models were used to test the association
between rs2660845 and asthma exacerbation status. Information related to age, gender, body
mass index (BMI), asthma, age onset and exacerbation status 12 months before the start of
therapy as well as the first two principal components of the genotype matrix, to control for
population stratification, were included as covariates where appropriate and available for each
study (S3 Table). The effect of the LTA4H variant was considered additive for this analysis. Sta-
tistically significant associations were considered for p-values (P) lower than 0.05. Regarding
the number of individuals selected we were sufficiently powered (>80%) to detect an OR of
1.5 or above based on our power calculation (S1 Table) [34].
Meta-analysis
Association results obtained from late-onset and early-onset studies were meta-analyzed sepa-
rately to investigate the age of onset effect. For early-onset, populations of European origin
were meta-analyzed together as well as with Latin/Hispanic and African American popula-
tions. Overall pooled odds ratios from all early-onset patients from GoSHARE(b), BREATHE,
Tayside RCT, PAGES, SAGE, and GALA II studies, together with 95% confidence interval of
the association between rs2660845 genotype and asthma exacerbation status, were obtained
using a random effects model, because the phenotype definition as well as study characteristics
varied among studies (Table 1). Whereas for late-onset Europeans studies (GoSHARE(a) and
the UKBiobank), as the phenotype definition and baseline characteristics (age, gender, exacer-
bation percentage) were similar, a fixed effects model was used. The analysis was performed
using the metafor package in R [35]. We tested the heterogeneity among studies by means of
the measure of inconstancy (I2) values as low (0–25%), moderate (25–50%) and high (50–
75%). A threshold of P<0.05 was used to assess the statistical significance of the main effect
association. All association tests were performed using an additive model.
Results
Study characteristics
Study type and baseline characteristics of the participants for each study are presented in
Table 1. A total of 3,594 individuals (2,514 late-onset and 1,080 early-onset) with asthma from
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multiple independent studies were used. More than 50% of the participants were female in
SAGE, the UKBiobank and GoSHARE (a and b) (55%, 66.5%, 56% and 79% female respec-
tively) and male in BREATHE, Tayside RCT, PAGES and GALA II (61%, 63%, 60%, 57% male
respectively). The proportion of early-onset and late-onset individuals experiencing an exacer-
bation before being on montelukast was between 12% and 22% for BREATHE, Tayside RCT,
GoSHARE and UKBiobank but was 67%, 72% and 73% respectively for PAGES, GALA II and
SAGE. The minor allele frequency of rs2660845 in the UKB, GoSHARE, BREATHE, Tayside
RCT, PAGES, GALA II and SAGE, study populations was 0.27, 0.27, 0.27, 0.28, 0.26, 0.46 and
0.32 respectively.
As a control analysis, we tested the association between rs2660845 and non-montelukast
users in both late-onset and early-onset (S4 Table). No significant association was observed
between rs2660845 and exacerbation rate in individuals with early or late onset not under
montelukast treatment (Tables 2 and 3).
Association between rs2660845 and exacerbation status under montelukast
treatment in Europeans with early-onset asthma
We assessed the risk of having an exacerbation whilst on montelukast treatment using an addi-
tive model. Table 4 shows the results of logistic regression models assessing the effect of
Table 1. Characteristics of the studied cohorts.
UKBiobank GoSHARE (a) GoSHARE (b) BREATHE Tayside RCT PAGES GALA II SAGE
N asthmatics 72,754 10,218 546 62 361 3,343 977
N montelukast
users
1,561 953 88 210 62 163 486 71
Asthma onset Late Late Early Early Early Early Early Early




% male (n) 33.5 44 21 61 63 60 57 45
Mean age (SD)
years













































0.27 0.27 0.27 0.27 0.28 0.26 0.46 0.32
1Exacerbation within 6 months
2Exacerbation within 12 months. OCS: Oral Corticosteroids, ER: Emergency Room visit. Asthma onset is defined as early.
https://doi.org/10.1371/journal.pone.0257396.t001
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rs2660845 on exacerbation status. The genotypic effect was noted in three out of four Euro-
pean early-onset asthma studies. In BREATHE and Tayside RCT, individuals carrying at least
a copy of rs2660845 G allele had respectively 4.4 (95%CI: 1.77–10.96, P = 0.05) and 9.6 (95%
CI:1.00–92.19, P = 0.001) times the odds of having an exacerbation, in an additive model
adjusted for age at recruitment and BMI. In GoSHARE (b), and PAGES the associations were
not significant in a model adjusted for age at first LTRA prescribed and exacerbation 12
months before date of first montelukast prescription (respectively Odds-ratio (OR) 4.5, 95%
confidence interval (CI): 0.77–26.24; P = 0.0913 and OR = 0.959; 95%CI: 0.427–2.15;
P = 0.668).
Association of rs2660845 with exacerbation status under montelukast
treatment in Latino/Hispanic and African American early-onset asthma
ethnic groups
In the Latino/Hispanic population, GALA II, the association was not significant (OR = 1.04;
95%CI: 0.78–1.39; P = 0.788). The African American population (SAGE) presented an oppo-
site nominal association with an OR of 0.27 (95%CI: 0.09–0.80; P = 0.019) in a model adjusted
by age of asthma onset, gender and the first two principal components (Table 4).
Meta-analyses of early-onset asthma cohorts
A meta-analysis of European early-onset cohorts PAGES, GoSHARE (b), BREATHE, Tayside
RCT revealed that carriers of at least one G allele of rs2660845 SNP have 2.92 (95%CI: 1.04–
8.18, P = 0.0412) times the odds of experiencing an exacerbation (Fig 2). When adding GALA
II (Latino/Hispanic) and SAGE (African American), where rs2660845 MAF is higher than in
European cohorts, no significant association between rs2660845 SNP and exacerbation status
was found (OR = 1.60, 95%CI: 0.61–4.19; P = 0.342) (Fig 3).
Table 3. Association between rs2660845 and exacerbation in individuals with early-onset asthma in PAGES and
BREATHE non-montelukast users and in GoSHARE(b) individuals 12 months before being on montelukast.
Study PAGES (n = 356) BREATHE (n = 94) GoSHARE(b) (n = 88)
OR (95% CI) 1.97 (0.927–4.187) 1.14 (0.246–5.36) 1.49 (0.532–4.18)
P-value 0.171 0.919 0.447
Odds of exacerbation rate on montelukast using an additive model adjusted for age, gender, age at 1st montelukast
prescription or age at asthma onset and BMI when significant and available.
GoSHARE(b): individuals with age at first salbutamol, age at first inhaled corticosteroid and age at first montelukast
prescription, all three under or at 18 years old.
https://doi.org/10.1371/journal.pone.0257396.t003
Table 2. Association between rs2660845 and asthma exacerbation in late-onset GoSHARE(a) individuals 12
months before being on montelukast.
Study GoSHARE(a) (n = 953)
OR (95% CI) 0.85 (0.641–1.127)
P-value 0.6388
Odds of exacerbation rate on montelukast using an additive model adjusted for age, gender, age at 1st montelukast
prescription or age at asthma onset and BMI when significant and available.
GoSHARE(a): individuals with age at first salbutamol, age at first inhaled corticosteroid and age at first montelukast
prescription, all three over 18 years old.
https://doi.org/10.1371/journal.pone.0257396.t002
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Lack of association between rs2660845 genotype and exacerbation status
under montelukast treatment in Europeans late-onset asthma and meta-
analysis
No association between exacerbation risk and LTA4H rs2660845 was seen in any of the late-
onset studies (Table 4).
A meta-analysis of the observed effects across late-onset populations of the UKBiobank and
GoSHARE(a) showed no significant association between rs2660845 genotype and exacerba-
tion status under montelukast treatment (OR = 1.02, 95%CI: 0.87–1.19 P = 0.833) (Fig 4).
Discussion
We report the results of the first study evaluating the association of the SNP rs2660845 with
asthma exacerbations whilst on montelukast treatment, in late-onset and early-onset asthma
patients, from different populations and ethnic backgrounds. We analyzed data from 3,594
individuals with asthma, 2,514 of which were late-onset and 1,080 early-onset.
Although no evidence of rs2660845 association with asthma was found in late-onset cohorts
of European ancestry, we observed a significant association (p = 0.0412) and heterogenous
Table 4. Association of exacerbation under montelukast treatment with rs2660845 genotype.
Asthma onset Late-onset Early-onset








BREATHE Tayside RCT PAGES GALA II SAGE
Odds ratio (95%CI) for


















P-value 0.965 0.33 0.0913 0.050 0.001 0.668 0.788 0.019
Odds of exacerbation rate on montelukast using an additive model adjusted for age, gender, age at 1st montelukast prescription or age at asthma onset and BMI when
significant and available.
Asthma onset is defined as early for individuals � 18 years old at asthma diagnosis and late for individuals over 18 years old at asthma diagnosis.
https://doi.org/10.1371/journal.pone.0257396.t004
Fig 2. Forest plot representing meta-analysis of the association between LTA4H rs2660845 and outcomes
observed across early-onset PAGES, GoSHARE(b), BREATHE and Tayside RCT studies. Study sample size is in
parentheses. Squares represent the odds ratio (OR), horizontal lines represent 95% confidence intervals (CIs). The
diamond in the bottom represents summary estimate combining the study-specific estimates using a random effects
model.
https://doi.org/10.1371/journal.pone.0257396.g002
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response in early-onset asthma carriers of rs2660845 G allele with the European cohorts
PAGES, GoSHARE(b), BREATHE and Tayside RCT (heterogeneity P = 0.0364). Higher het-
erogeneity was found with ethnically different early-onset populations for association between
rs2660845 and exacerbation whilst on montelukast treatment (heterogeneity P = 0.0007), with
the odds ratio being lower in the African American cohort SAGE and not significant in the
Latino/Hispanic cohort GALA II. As our study identifies the rs2660845 genotype as associated
with positive, negative and neutral effect on outcome in different populations, mechanistic
studies would be required to confirm its relevance to LTRA response in different ethnic
groups. However, rs2660845 represents a putative biomarker for prediction of montelukast
response in Europeans with early-onset asthma.
Since early-onset and late-onset asthma present fundamental differences both in the estab-
lishment of disease, as well as genetic variation and expression [3–7], we chose to analyse the
effect of LTA4H rs2660845 SNP in each onset group. We found that the age of onset plays a
role in the response to montelukast in European early-onset asthma patients, where the SNP
Fig 3. Forest plot representing meta-analysis of the association between LTA4H rs2660845 and outcomes
observed across all early-onset GALA II, SAGE, PAGES, GoSHARE(b), BREATHE and Tayside RCT studies.
Study sample size is in parentheses. Squares represent the odds ratio (OR), horizontal lines represent 95% confidence
intervals (CIs). The diamond in the bottom represents summary estimate combining the study-specific estimates using
a random effects model.
https://doi.org/10.1371/journal.pone.0257396.g003
Fig 4. Forest plot representing meta-analysis of the association between LTA4H rs2660845 and outcomes
observed in late-onset UKBiobank and GoSHARE(a) studies. Study sample size is in parentheses. Squares represent
the odds ratio (OR), horizontal lines represent 95% confidence intervals (CIs). The diamond in the bottom represents
summary estimate combining the study-specific estimates using a random effects model.
https://doi.org/10.1371/journal.pone.0257396.g004
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rs2660845 was significantly associated with heterogenous montelukast response as measured
by exacerbation rate. These results were consistent with previous studies where early-onset
asthma is presented as more genetic and allergic driven than late-onset which tends to be more
environmental and lung centred [7, 36].
There are significant disparities in asthma prevalence, mortality and drug response between
ethnic groups [37]. Here we reported different results from four European early-onset cohorts,
one Latino/Hispanic and one African American, with rs2660845 MAF higher in GALA II and
SAGE populations (results consistent with gnomAD [38]) compared to the European studies.
Previous sequencing of LTA4H in GALA II revealed the prevalence of five polymorphisms
[39] differing from those found in a European cohort by Holloway et al [40]. It is possible that
ancestry-specific differences in genetic architecture (linkage disequilibrium patterns) may
explain why rs2660845 SNP shows no or significant opposite effects in different populations.
Furthermore, heterogeneous effects may also be combined with differences in the environ-
mental background between African American, Latino and European populations as well as
insufficient sample size [41, 42]. Also as PAGES, GALAII and SAGE, presented a higher
exacerbation percentage before montelukast treatment, it is possible that those higher exacer-
bation percentage explain the high heterogeneity found between early-onset asthma cohorts
and so the difference in the outcome. As environmental factors can modulate the effect of
genetic variants upon asthma patients [42, 43] or drug response, and we were not able to inves-
tigate these cohorts more in depth to determine what environmental factor was driving this
difference, it is important to note that we might underestimate the effect of rs2660845 SNP on
montelukast response in the European early-onset meta-analysis. Another important driver of
the heterogeneity found here is the asthma exacerbation definition.
An indirect role of rs2660845 on asthma exacerbation has been suggested by Rao et al., with
the inactivation of LTA4H resulting in less exacerbations [44]. Leukotriene-B4 (LTB4), the
product of the degradation of leukotriene-A4 by LTA4H, plays a role in recruiting CD4
+,
CD8+ and T-cells and thus triggering lung inflammation and airway responsiveness [45].
Therefore, an inactivation of LTA4H would affect those inflammatory cells recruitment by
lowering LTB4 concentration in the blood. As LTB4 levels in the airways have been shown to
increase in blood and bronchoalveolar lavage of asthma patients [46–48] and to correlate with
asthma severity [49, 50], we examined mRNA expression data from whole blood in the GTEx
[51], eQTLGen [52] and BIOSQTL [53] databases. We found that rs2660845 SNP is associated
with LTA4H expression, with AA genotype lowering the expression (S2 Fig and S7 Table).
rs2660845 is present in the 5’UTR regulatory region of LTA4H, indicative of a putative cis-
eQTL effect. However, the gene expression data analyzed was collected from adults of Euro-
pean ancestry (S1A and S1B Fig for GTEx) and no significant association was found between
rs2660845 and montelukast response in an adult cohort of early-onset asthma from the
UKBiobank (S5 and S6 Tables). As LTA4H expression and effects have been shown to be dif-
ferent in late-onset and early-onset asthma [7], it is possible that the results would be signifi-
cant in a pediatric study. A possible mechanism in early-onset asthma is presented in Fig 5. By
down regulating LTA4H activity, individuals with a rs2660845 AA genotype have a reduced
LTB4 blood concentration resulting in less LTB4 driven exacerbations, simultaneously monte-
lukast, acting as a cysteinyl receptor antagonist, will prevent other products of LTA4 degrada-
tion by leukotriene C4 synthase from binding to the receptor, thus reducing exacerbations
through this arm of the LTA4 pathway. Therefore, LTA4H inhibitors, 5-Lipoxygenase Activat-
ing Protein inhibitors and Leukotriene-B4 receptor antagonists might represent a potential
therapeutic strategy that could modulate key aspects of early-onset asthma [40, 54].
Our study has limitations that should also be considered. A fine mapping of the LTA4H
locus or haplotype analysis as reported by Holloway and colleagues [40] may help our
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understand the relationship between genetic variants of LTA4H, but was prevented by either
GWAS or haplotype data being unavailable for all cohorts. We decided to focus on rs2660845
as literature indicated a putative association with outcomes for asthma treatment [17] and rep-
licated this result in our European early-onset cohorts despite a high heterogeneity between
studies. Differences in patient recruitment (GP selection vs prescriptions-base selection, GP
selection between asthma studies) and definition of asthma exacerbation despite LTRA treat-
ment such as time frame variation of 6 to 12 months between longitudinal cohorts and asthma
study as well as between asthma studies, exacerbation markers used in only one or two cohorts
(school absence for BREATHE, PAGES and Tayside RCT, at least two OCS prescriptions for
UKB and GoSHARE) explained a large part of this heterogeneity. Within ethnic group differ-
ences could also be a driver of the high heterogeneity found here as it can be more significant
than heterogeneity across different ethnic groups. Moreover, another potential source of varia-
tion came from the use of retrospective information about the occurrence or absence of
asthma exacerbations, partly based on self-reporting within asthma studies.
Another important limitation is that we were not able to account for any aetiology of
asthma exacerbations as well as exposure to potential environmental triggers such as smoking,
one of the most important environmental factors knowing its impact on lungs. Unfortunately,
the information was not collected in a similar way for all studies, with only second-hand smok-
ing information available for the pediatric cohorts (PAGES, BREATHE, Tayside RCT, GALAII
and SAGE) and primary smoking status only available for a subset of GoSHARE and the
UKBiobank cohorts. Finally, we have also assumed that treatment has been assigned based on
similar prescribing criteria and did not take into consideration specific LTRA dose and type or
any index of treatment adherence (BTS/SIGN guidelines) since information related to these
variables was not available for most of the studies included. We also did not investigate other
treatments and it is possible that individuals with increased risk of exacerbation might not
have received LTRA treatment which would tend to underestimate the effect of the interaction
between montelukast and rs2660845 for exacerbations. As other treatments were not taken
into account, the effect found in the early-onset asthma group could also be overestimated and
mostly linked to a more serious disease. Altogether, this heterogeneity in data availability
could represent a potential interpretation bias in terms of response to asthma treatment.
Fig 5. A possible mechanism of SNPs rs2660845 action on montelukast response in pediatric asthma patients.
Reduced risk of exacerbation might be due to the down regulation of LTA4H activity, stimulating a montelukast
sensitive pathway triggering exacerbation. rs2660845 AA genotype would result in a comparatively reduced LTA4H
expression, leading to lowered LTB4 concentrations and so reducing exacerbation triggered by BLT receptors.
Furthermore, LTA4 would be more readily converted into LTC4, unable to bind to CysLT1 receptors already blocked
by montelukast.
https://doi.org/10.1371/journal.pone.0257396.g005
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To our knowledge, this is the only study of leukotriene response to utilize populations of
different age of onset and different ethnic backgrounds. These results, together with published
studies in other European [40] and Latino/Hispanic cohorts [39], support a strong involve-
ment of age of onset, LTA4H and LTB4 production in the pathophysiology of asthma. Our
results add to the growing evidence of age of asthma onset as a robust clinical biomarker and
moreover suggest stratifying treatment by age of asthma onset and rs2660845 status can form
the basis of a precision medicine strategy to select those patients most likely to benefit from
montelukast treatment.
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